(Ivanhoe Newswire) -- A genetic signature may help predict which breast
cancer patients are resistant to chemotherapy drugs, something that may guide
treatment choices.
The genes were discovered by a group at the Dana-Farber Cancer Institute, who
examined breast tumor specimens from 85 patients. The genetic signature occurred
in about one in five samples and were linked to poorer treatment outcomes.
Breast cancers with the genes are resistant to the anthracycline class of drugs,
but may still be vulnerable to other types of chemotherapies, researchers say.
This new information could lead to the development of a genetic test of breast
cancers to help doctors decide the best treatment for each individual.
With the exception of a few patients, "No tests are done before treatment begins
to predict who's going to be resistant or sensitive to different compounds,"
Andrea Richardson, M.D., Ph.D., study investigator and also a faculty member of
Brigham and Women's Hospital in Boston, Mass., was quoted as saying. "Most
breast cancer patients are initially given the same drugs."
Source: Nature Medicine, published online January 24, 2010
